[1]
|
Fabiola, A., Chiara, M.G., Giuseppe, B., et al. (2018) Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: A Comprehensive Review. Expert Review of Clinical Immunology, 14, 69-82.
https://doi.org/10.1080/1744666X.2018.1411190
|
[2]
|
Suha, K. and Ganesh, R. (2021) Rheumatoid Arthri-tis-Interstitial Lung Disease: Manifestations and Current Concepts in Pathogenesis and Management. European Respira-tory Review, 30, Article ID: 210011.
https://doi.org/10.1183/16000617.0011-2021
|
[3]
|
Spagnolo, P., Distler, O., Ryerson, J.C., et al. (2020) Mecha-nisms of Progressive Fibrosis in Connective Tissue Disease (CTD)-Associated Interstitial Lung Diseases (ILDs). Annals of the Rheumatic Diseases, 80, 143-150.
https://doi.org/10.1136/annrheumdis-2020-217230
|
[4]
|
Ayodeji, A., et al. (2019) Computed Tomography Honey-combing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Annals of the American Thoracic Society, 16, 525-646.
https://doi.org/10.1513/AnnalsATS.201807-443OC
|
[5]
|
刘燕, 施春花. 结缔组织病相关性间质性肺疾病诊断的研究进展[J]. 实用临床医学, 2023, 24(4): 118-124.
https://doi.org/10.13764/j.cnki.lcsy.2023.04.031
|
[6]
|
郭友芳, 张薇, 冯明发, 王梦瑶. 特发性肺纤维化治疗进展[J]. 临床肺科杂志, 2021, 26(10): 1591-1594.
|
[7]
|
李江蕾, 何芸. 结缔组织病相关肺间质病诊治研究进展[J]. 云南医药, 2022, 43(1): 76-78.
|
[8]
|
代华平. 纤维化间质性肺疾病——早期识别与干预[J]. 国际呼吸杂志, 2021, 41(21): 1601-1604.
https://doi.org/10.3760/cma.j.cn131368-20211026-00794
|
[9]
|
Olson, A., Hartmann, N., Patnaik, P., et al. (2020) Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Advances in Therapy, 38, 854-867.
https://doi.org/10.1007/s12325-020-01578-6
|
[10]
|
Wells, A., Devaraj, A., Renzoni, E.A. and Denton, C.P. (2019) Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 40, 184-193.
https://doi.org/10.1055/s-0039-1684020
|
[11]
|
舒适, 代华平. 进展性纤维化间质性肺疾病的诊治进展[J]. 临床内科杂志, 2022, 39(10): 659-662.
|
[12]
|
陈卫松, 陈伟, 陈慧, 等. 肺组织密度对早期诊断结缔组织病相关间质性肺病的价值[J]. 全科医学临床与教育, 2019, 17(5): 456-457, 459. https://doi.org/10.13558/j.cnki.issn1672-3686.2019.05.022
|
[13]
|
徐光兴, 俞咏梅, 徐亮, 王蓓蓓, 吴树剑. 皮肌炎/多发性肌炎并发间质性肺病的CT定量分析与肺功能的相关性研究[J]. 放射学实践, 2023, 38(5): 565-570. https://doi.org/10.13609/j.cnki.1000-0313.2023.05.006
|
[14]
|
尹健彬, 皮娜, 文怡, 刘婵, 李佳鑫, 成梦群, 白子娟, 张旋. 肺纤维化小鼠肺功能的动态变化[J]. 医学研究生学报, 2019, 32(12): 1237-1242. https://doi.org/10.16571/j.cnki.1008-8199.2019.12.002
|
[15]
|
孙英梅, 马瑞雪, 闫慧明. 结缔组织病相关间质性肺病部分生物标志物的研究进展[J]. 风湿病与关节炎, 2023, 12(9): 76-80. https://doi.org/10.3969/j.issn.2095-4174.2023.09.018
|
[16]
|
周毓, 周玉祥, 叶凯. KL-6在结缔组织病相关间质性肺病中的诊断及预后评估价值研究[J]. 中国实用医药, 2023, 18(10): 26-30. https://doi.org/10.14163/j.cnki.11-5547/r.2023.10.006
|
[17]
|
杨刘敏, 马天罡, 吕雪娇, 等. 肿瘤标志物与结缔组织病相关间质性肺病的相关性[J]. 中国老年学杂志, 2022, 42(21): 5407-5411.
|
[18]
|
颜菲, 范观止, 刘一平, 等. 血清肿瘤标志物检测在结缔组织病相关间质性肺疾病患者中的临床意义[J]. 中国医科大学学报, 2023, 52(2): 153-159. https://doi.org/10.12007/j.issn.0258-4646.2023.02.011
|
[19]
|
梁启刚, 杨薇, 沈宁. 支气管肺泡灌洗液在结缔组织病相关间质性肺疾病中的应用[J]. 内科急危重症杂志, 2017, 23(4): 343-347.
|
[20]
|
Troy, K.L., Grainge, C., Corte, J.T., et al. (2020) Diagnostic Accuracy of Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Di-agnosis (COLDICE): A Prospective, Comparative Study. The Lancet Respiratory Medicine, 8, 171-181.
|
[21]
|
Kurnvir, S., Mohammed, A., Romy, O.R., et al. (2019) Interstitial Lung Disease as the Initial Manifestation of Rheumatoid Arthri-tis: A Case Report and Review of the Literature. American Journal of Medical Case Reports, 7, 342-347. https://doi.org/10.12691/ajmcr-7-12-10
|
[22]
|
Papiris, S.A., Lykourgos, K., Konstantinos, K., Maniati, M. and Manali, E.D. (2022) IPF-Acute Exacerbations: Advances and Future Perspectives. Frontiers in Pharmacology, 13, Arti-cle 836553.
https://doi.org/10.3389/fphar.2022.836553
|
[23]
|
霍荣秀, 郭乾育, 许珂. 药物治疗结缔组织病相关间质性肺疾病的进展[J]. 中华风湿病学杂志, 2022, 26(7): 489-493. https://doi.org/10.3760/cma.j.cn141217-20210311-00099
|
[24]
|
陈冰琳, 薛美娟, 杨骥, 等. 系统性硬化症相关间质性肺病的诊治现状和进展[J]. 中华皮肤科杂志, 2020, 53(1): 66-71. https://doi.org/10.35541/cjd.20180838
|
[25]
|
林茂煌, 张淇钏. 结缔组织病致肺间质病变临床表现特点、生理指标变化及干预效果分析[J]. 现代诊断与治疗, 2015(10): 2161-2163.
|
[26]
|
张小飞. 结缔组织病相关间质性肺疾病合并肺部感染的临床特点及危险因素分析[D]: [硕士学位论文]. 广州: 广州医科大学, 2018. https://doi.org/10.7666/d.D01553177
|
[27]
|
刘玉端, 李艳杰, 省一博. 甲泼尼龙联合甲氨蝶呤治疗RA患者的临床疗效研究[J]. 医药论坛杂志, 2021, 42(20): 75-78.
|
[28]
|
项惟真, 董蓉蓉, 李美琪, 麻贞贞, 杨清锐. 生物制剂治疗类风湿关节炎相关间质性肺病疗效与安全性的meta分析[J]. 中南药学, 2023, 21(4): 1062-1069.
|
[29]
|
邢楠舒, 张榕. 生物制剂及小分子靶向药物治疗CTD-ILD[J]. 中华临床免疫和变态反应杂志, 2020, 14(5): 495-499.
|
[30]
|
王潇, 岳红梅, 王若利, 等. 吡非尼酮对结缔组织病相关间质性肺疾病的治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(5): 584-590.
|
[31]
|
吴聪, 刘建, 郭亚丽, 王玉光. 进展性纤维化型间质性肺疾病药物治疗的研究进展[J]. 世界中西医结合杂志, 2021, 16(11): 2151-2156. https://doi.org/10.13935/j.cnki.sjzx.211141
|
[32]
|
张冰璐, 欧阳松云, 代丽萍, 陈瑞英, 赵春玲. 抗纤维化药物在结缔组织相关间质性肺炎中的应用价值与疗效评估[J]. 临床肺科杂志, 2023, 28(5): 663-667.
|
[33]
|
中国医师协会风湿免疫科医师分会风湿病相关肺血管/间质病学组, 国家风湿病数据中心. 2018中国结缔组织病相关间质性肺病诊断和治疗专家共识[J]. 中华内科杂志, 2018, 57(8): 558-565.
https://doi.org/10.3760/cma.j.issn.0578-1426.2018.08.005
|
[34]
|
顾芬, 王琳. 重视慢性肺部疾病的早期肺康复护理[J]. 结核与肺部疾病杂志, 2022, 3(3): 177-180.
https://doi.org/10.19983/j.issn.2096-8493.20220074
|
[35]
|
赵青, 赵红梅. 间质性肺病的呼吸康复治疗[J]. 国际呼吸杂志, 2020, 40(9): 689-692.
https://doi.org/10.3760/cma.j.cn131368-20191225-01817
|
[36]
|
Krzysztof, W., Anna, H., Paweł, P., et al. (2020) Pulmonary Rehabilitation in Interstitial Lung Diseases: A Review of the Literature. Advances in Clinical and Experi-mental Medicine, 29, 257-264. https://doi.org/10.17219/acem/115238
|